Jeffrey Jones to Leukemia, Lymphocytic, Chronic, B-Cell
This is a "connection" page, showing publications Jeffrey Jones has written about Leukemia, Lymphocytic, Chronic, B-Cell.
Connection Strength
1.700
-
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75.
Score: 0.576
-
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018 01; 180(2):259-266.
Score: 0.575
-
Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017 Aug 01; 127(8):3052-3064.
Score: 0.140
-
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol. 2015 Nov; 90(11):967-9.
Score: 0.124
-
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr; 1(1):80-7.
Score: 0.120
-
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease. Br J Haematol. 2010 Mar; 148(5):754-9.
Score: 0.083
-
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009 Dec 10; 27(35):6012-8.
Score: 0.082